Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26

Loading news article.

Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26 | WAPE

Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26

Article summary

Related companies

Comments —